Review decision – May 2021
Decision that a review of the guidance should be planned into the appraisal work programme
We would like to update you on the decision made regarding the existing NICE technology appraisal guidance on dexamethasone intravitreal implant for treating diabetic macular oedema.
The company has indicated that there is new evidence for the clinical and cost effectiveness of dexamethasone intravitreal implant for treating an eye that does not have a pseudophakic lens and with diabetic macular oedema that does not respond to non-corticosteroid treatment, or for which such treatment is unsuitable.
Consequently we propose that a part-review and part re-issue of the guidance should be planned into the appraisal work programme.
NICE’s Guidance Executive has decided to proceed with this proposal without consultation.
This page was last updated: